cyrilzakka/clinical-trials huggingface dataset:
Effect of Nicotinamide Riboside and Pterostilbene Supplementation on Muscle Regeneration in Elderly Humans

Successful skeletal muscle regeneration depends on a functional pool of muscle stem cells, termed satellite cells (SC). SC are in a quiescent state throughout adulthood, but undergo multiple cycles of proliferation and self-renewal in response to muscle damage. During aging, there is a loss of SC quiescence, and SC more readily enter an ageing-state impairing their function.

Animal studies have revealed a common denominator for increasing SC function and activity, namely Sirtuin activation. Natural stimulators of Sirtuins includes Nicotinamide Riboside (NR) (a Nicotinamide adenine dinucleotide (NAD+) precursor) and the polyphenol Pterostilbene (PT). In this study, we aim to investigate if NR+PT supplementation will promote skeletal muscle regeneration after muscle damage in elderly humans by enhanced recruitment of SC.

14 days after start of placebo or NR/PT (500/100 mg twice daily) supplementation a muscle damage will induced in the m. vastus lat. by electric stimulation combined with eccentric work in a dynamometer. Muscle biopsies will be collected at 2 hours, 2, 8 and 30 days post damage and placebo or NR/PT supplementation will continue for the whole study period (45 days).

Eligibility Criteria:
Inclusion Criteria:

* Written signed consent
* Age: 55-80
* BMI: 20-28 (kg/(m2))
* Non-smoker

Exclusion Criteria:

* Endocrine disease, neurological or muscle disease
* Other severe disease
* High daily activity level (\>30 min / day)
Role of Ultrasound in Inflammatory Bowel Disease

The aim of this article is to provide an extensive overview of the actual role of bowel ultrasound in the detection and follow-up of patients with chronic inflammatory bowel disease

The inflammatory bowel disease is a chronic bowel disorder; it can involve the whole gastrointestinal tract, but its localization in the ileum or colon is most common. The reference standard for the diagnosis of inflammatory bowel disease is ileocolonoscopy with histologic assessment. Dan Carter, Lior H. Katz, Eytan Bardan, Eti Salomon, Shulamit Goldstein, Shomron Ben Horin, Uri Kopylov, and Rami Eliakim The reference standard for the detection of any complications is surgery. However, imaging techniques have an important role both in the detection/localization of C D and in the followup of C D patients. In the last few years, the technical development of ultrasound equipment, the advent of new technologies such as elastography and mostly the increased expertise of sonographers have boosted the role of bowel ultrasound in assessment of the gastrointestinal tract. In fact, bowel ultrasound is particularly attractive thanks to its widespread availability, non-invasiveness, low cost and good reproducibility, as it can be easily repeated during follow-up Clara Benedetta Conti , Mariangela Giunta , Daniele Gridavilla , Dario Conte , Mirella Fraquelli . Bowel ultrasound has become the first-line imaging technique for patients with suspected C rohn's disease because it is cheap ,less radiation effect ,it can be done more than one time for follow up these patient . Some signs, for example, bowel loop elasticity (i.e., the capability of the bowel wall to collapse on the bowel lumen and return to the original size and shape after manual compression and decompression) and compressibility at probe contact and peristalsis (usually impaired), are not specific, whereas other signs, such as the characteristics of the bowel wall, are more specific. Among the latter, the most important sign is bowel wall thickening (BWT) . Also important are bowel wall echo pattern characteristics (BWP) , the presence of any margin irregularity and the grade of vascularity at echo color Doppler or power Doppler . Other yet less frequent signs are the luminal alterations, such as the distension or any luminal stenosis. Other possible findings outside the bowel loop are mesenteric hypertrophy , enlarged mesenteric lymph nodes and free fluid in the abdominal cavity or among the bowel loops .

Eligibility Criteria:
Inclusion Criteria:

* All patient reffered to radiology department for doing ultrasonography suspected to have bowel disease.

Exclusion Criteria:

* No patient excluded to do this process.
Effect of Food on Pharmacokinetics of Salvianolic Acid A in Healthy Subjects

This study is an open-label, randomized, cross-over design with two single-dose treatment periods and a washout of at least 3\~5 days in between each treatment visit. The study period consists of 3 visits to the study centre: Visit 1 (enrolment), Visit 2 (first single-dose treatment), Visit 3 (second single-dose treatment).

Target subject population is healthy subjects aged 18-45 years. Following an overnight fast of at least 10 hours, a single dose of 90mg salvianolic acid A will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.


Eligibility Criteria:
Inclusion Criteria:

1. healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥19.0 and ≤25.0 kg/m2 at screening
2. The subject is able to communicate well with the investigator and is able to complete the trial in accordance with the protocol.

Exclusion Criteria:

1. Planned for pregnancy or pregnant within 6 months after enrollment throughout the trial.
2. Subject has any clinically significant abnormal finding on the physical exam at screening or admission.
3. Subject has a positive screening test for alcohol or drugs of abuse at screening or admission.
4. Allergic to the body.
5. Participated in any clinical trial within 3 months prior to the trial.
Vigabatrin Ph 1 Cocaine Interaction Study

This is a Phase 1 safety/tolerably study to determine if there are clinically significant interactions between oral vigabatrin (gamma vinyl-gamma-amino butyric acid; VGB) concurrent with intravenous (IV) cocaine infusions.

STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of the effects of VGB compared to placebo control on the physiological and subjective effects of IV infusions of cocaine (cocaine experienced volunteers).

Subjects will be randomized within each clinical site to one of four groups (placebo control or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will receive double-blind infusions of saline and cocaine. Subjects will be asked to return for follow-up approximately 7 and 14 days after the day of clinic discharge.

STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments and investigational products administration, and two follow-up visits after clinic discharge.

SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or placebo.

POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45 years of age.

Eligibility Criteria:
Inclusion Criteria:

* Be between 18 and 45 years of age, inclusive
* Currently be a non-treatment seeking cocaine user as confirmed by a positive urine test for cocaine
* Able to provide written informed consent
* A negative pregnancy test within 72 hours prior to receiving the first infusion of cocaine

Exclusion Criteria:

Please contact site for more information.
Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.


Eligibility Criteria:
Inclusion Criteria:

* Patient over 18 years
* Inpatient orthopedic surgery
* Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)
* Bacteria resistant to lincosamides, quinolones and rifampicin
* Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)
* Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)

Exclusion Criteria:

* Patient not affiliated to the social security
* Pregnant and lactating women
* Known hypersensitivity to teicoplanin (rash, ...)
* Patients with a central catheter or an implantable chamber
* Patient hemodialysis
* Patient has another participant biomedical research on a drug to prevent drug interactions
* Patient minor
* Patient major protected (protection of the court, wardship, trusteeship)
* Patient admitted for emergency or incapable of consent
PRECOG Pilot Project

This pilot study aims to investigate the chronic effects of a prebiotic blend on cognitive, affective and gut microbiome outcomes in healthy adults aged 60-75 years.

This pilot study will employ a double-blind, randomised, placebo-controlled parallel design to investigate the chronic effects of 12-week-long prebiotic blend consumption on cognitive, affective, gut microbiome, metabolic, and anthropometric outcomes in healthy older adults with mild to moderate subjective cognitive complaints. Fifty participants will be randomised to Intervention or Placebo groups where they will be consuming 10g of prebiotic fibre blend or 10g of placebo (matched placebo powder) per day for 12-weeks. Outcome measures will be acquired before and after a 12-week chronic supplementation. These will include cognitive measures of overall cognitive functioning, and domain-specific cognitive performance, affective measures of depression and anxiety symptomatology; gastrointestinal symptomatology; systolic and diastolic blood pressure, as well as height, weight, hip and waist circumference. In addition, stool samples will be collected at all timepoints to assess microbiome diversity and composition.

Eligibility Criteria:
Inclusion Criteria:

* Aging between 60-75 years old
* Having normal vision and hearing
* Having a normal body mass index (BMI\<30)

Exclusion Criteria:

* Having mild to moderate subjective cognitive complaints
* Smoking
* Having food allergies
* Following restrictive and/or unbalanced diets
* Changing dietary intake majorly in past month
* Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders
* Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or suffering from hypertension or thrombosis related disorders or suffer from thyroid disease
* Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors
* Currently consuming prebiotic or probiotic supplements
* Continuous antibiotic use for \> 3 days within 1 month prior to enrolment
* Continuous use of weight-loss drug for \> 1 month before screening
* Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years
* Having a high fibre intake defined as \> 20g of fibre/day
* Wheat and/or gluten intolerance and having coeliac disease
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.

The main objective of this study is to assess the safety and effectiveness of the sirolimus coated Bx VELOCITY stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the bare metal Bx VELOCITY balloon-expandable stent. Both stents will be mounted on the Raptor Rapid Exchange Delivery Stent System.

This is a multicenter (19 sites), prospective, randomized study. This study has a 2 arm design assessing the safety and effectiveness of the sirolimus coated BxTM VELOCITY stent to the bare metal BxTM VELOCITY stent, both mounted on the Raptorâ Rapid Exchange Stent Delivery System. A total of 220 patients will be entered in the study and will be randomized on a 1:1 basis. Patients will be randomized to the coated or uncoated BX VELOCITY stent. Therefore, neither the Investigator nor the patient will know which stent will be implanted. Patients will be followed for twelve months post-procedure, with all patients having a repeat angiography at 6 months. An ancillary study with in-stent IVUS measurements at 6 months follow-up will be performed in all patients of 6 pre-selected clinical sites. It is assumed that these sites will enroll more than 90 patients.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia;
2. Single treatment of de novo lesion in a coronary artery which can be appropriately covered by a study stent of 18mm in length in patients with single or multivessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment;
3. Target lesion is \>= 2.5 and \<= 3.5mm in diameter (visual estimate);
4. Target lesion is located in a native coronary artery which can be covered by one stent (single lesion);
5. Target lesion stenosis is \>50% and \<100% (TIMI I) (visual estimate).

Exclusion Criteria:

1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the CK and CK-MB enzymes are back to normal;
2. Unprotected left main coronary disease with \>=50% stenosis;
3. Have an ostial target lesion;
4. Angiographic evidence of thrombus within target lesion;
5. Calcified lesions which cannot be successfully predilated;
6. Ejection fraction \<=30%;
7. Totally occluded vessel (TIMI 0 level);
8. Target lesion involves bifurcation including a side branch \>=2.5mm in diameter (either stenosis of both main vessel and major branch or stenosis of just major branch) that would require side branch stenting which is likely to occur if side branch is diseased and intended to be stented;
9. Planned Direct Stenting.
Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

This is an observational study collecting patient/caregiver reports on suspected medication/drug-induced acute porphyria attacks, as well as safe use of drugs previously labeled "unsafe" or with unknown risk. Participants will be recruited through the RDCRN Contact Registry for the Porphyrias Consortium. The study will be advertised on the Consortium website and through the American Porphyria Foundation's social media network.

Contact Registrants will be sent an email invitation describing the study. A unique link will be generated for each registrant and included in the email invitation. After 2 weeks, a second email invitation will be sent to the registrants who have not yet participated. After 1 month, a third email invitation will be sent to the registrants who have not yet participated. We may send additional emails periodically (e.g. every 6-12 months) to subjects enrolled to remind them to complete new surveys if they have taken any other medications of interest or have experienced any new reactions/attacks.

If the registrant wants to participate in the study, he/she will follow the survey link in the email invitation, which directs him/her to an IRB-approved online consent form. If the participant consents to participate, he/she will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and "uneventful use of possibly risky medication". If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of "Medications of Interest" and report current or past use.

Eligibility Criteria:
Inclusion Criteria:

* Able to read and write in English
* Enrolled in the RDCRN PC Contact Registry
* Self-reported patient or caregiver of patient with acute porphyria

There are no restrictions on age, sex or ethnicity. However, the following criteria will be applied to those reports that are considered evaluable (analyzed and scored):

1. Medication name must be specified
2. The data elements required in the scoring system must be complete

Exclusion Criteria:

* Unable to provide informed consent and complete forms
Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan

The lethal severe acute respiratory syndrome coronavirus 2 (SARS-COV2) which caused the COVID-19 pandemic starting at the end of 2019 has affected the lives of children and adolescents globally. world adopted the lockdown to prevent spread of the infection and protect the population. lockdown suspended out of home activities of almost everyone, along with health benefits, yielding some side effects as well including burnout. The burnout includes physical and emotional burnout, physical burnout refers to the lack of interest in any physical activity to the point of a rebel and the emotional burnout of teenagers refers to a syndrome including features such as behavior changes, thinking change, feeling change, health change leading to stress and other pathological disturbances. Together the external and internal factors lead to overall personality destruction.

It was an observational study with a sample size of 443 participants.

Objective of the study was to analyze the change in behavioral patterns, its impact, and peer pressure caused by lockdown during Pandemic COVID-19 among the adolescent population of Sialkot Pakistan.

It was an observational study with a sample size of 443 participants. The study was conducted after ethical approval by Institutional Review Board, Sialkot college of Physical Therapy wide Reference no. SCPT-IRB-DPT-129-2020 dated 01-09-2020. Data were collected from different institutions in Sialkot, Pakistan. The target population of our study was adolescents of age 13-19 years. Regression analysis was done to find the predictor factors mobile use and COVID-19 lockdown on the dependent variable the Burnout score. The correlation was applied among mobile phone use, lockdown, and burnout score.

Eligibility Criteria:
Inclusion Criteria:

* students of the above age group who started to go to the school/ colleges/ university/Academies.
* those who consent to participate in the study.

Exclusion Criteria:

* students who were unable to visit their institution and stayed at home.
Spermidine Intake and All-cause Mortality

This study seeks to test the potential association between spermidine content in diet and mortality in humans.

This prospective community-based cohort study includes 829 participants aged 45-84 years, 49.9% of which are male. Diet is assessed by repeated dietician-administered validated food-frequency questionnaires (2540 assessments) in 1995, 2000, 2005, and 2010. Nutrient intakes including spermidine are calculated using USDA standard databases. Clinical events (all-cause mortality and cause-specific mortality) are recorded from 1995 to 2015.

The primary endpoint of all-cause mortality is related to the exposure of long-term average spermidine intake by Cox proportional hazards models with time-varying covariates. Additional analyses employ the Fine and Gray proportional subdistribution hazards model and flexible Royston-Parmar spline-based models. Comprehensive sensitivity analyses are performed to guard against potential biases associated with nutritional epidemiology.

Eligibility Criteria:
Inclusion Criteria:

Resident of Bruneck aged 40-79 years in 1990, age- and sex-stratified random sample.

Exclusion Criteria: None.
The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

This study was a single center, parallel, randomized, double blind, placebo-controlled phase Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127 tablet in healthy subjects by increasing multiple dosing

Three panels(100mg, 200mg, 400mg), each consisting of eight participants (The number of individual subjects in each group was not less than 1/3 of the total number).Participants begin to receive the first dose of SPH3127 100mg. Then Participants begin to receive the second dose of SPH3127 200mg,after the researchers confirmed that the 100mg dose group was safe and well tolerated.Then the third dose of SPH3127 400mg must wait for the result of the second dose's safety and tolerability. If the subjects during escalating dose to the biggest tolerate dose group were not well tolerated, the study must adjust the maximum dose group and fall to a low dose group to conduct another test.

Eligibility Criteria:
Inclusion Criteria:

1. The body mass index is 18-28kg/m2 (including the critical value), which allows the minimum weight of men to be 50kg (including the critical value) and 45kg for women (including the critical value).
2. Before the study,participant has know about the significance , potential benefits, inconveniences and potential risks of the study
3. Participant has understood the research's procedure and sign the informed consent .

Exclusion Criteria:

* Participant who are Pregnancy, lactating women, and planned trials begin within six months of pregnancy
* Participant who has abnormal Physical examination, laboratory examination results and clinical significance (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal)
* Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality
* Participant who has drug allergy history and anaphylactic reaction
* Participant who took oral contraceptive in 6 months
* Participant who used any drug (including Chinese herbal medicine) within 1 week.
* Participant who donated blood within 2 months
* Participant who participated clinical trials of any drug in 3 months (as subjects)
* Participant who has any positive result of virus serology check: human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - immunoglobulin G(IgG) antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP)
* Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug abuse
* Participant who the researchers believe that there are volunteers who are not suitable for the study